All In Biotech

Drug Trial Radar · NCT06497491

An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease

A Single-blind Randomized Study of the Efficacy and Safety of the GNR-086 (Canakinumab Proposed Biosimilar) in Comparison With the Ilaris®, Conducted in Parallel Groups of Patients With Adult-onset Still's Disease

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Dec 12, 2023

Primary completion

May 29, 2025

Study completion Jul 10, 2025

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized single-blind comparative parallel group study of the efficacy and safety of canakinumab biosimilar GNR-086 (JSC \"GENERIUM\", Russia) and Ilaris® (Novartis Pharma Stein AG, Switzerland) in the treatment of patients with adult-onset Still\'s disease. Participants will receive a subcutaneous canakinumab 4 mg/kg every 4 weeks. The treatment duration is 24 weeks following with the study extension.

Conditions

  • Still's Disease Adult Onset

Interventions

  • GNR-086Biological

    GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.

  • Ilaris®Biological

    Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with a clinically significant (>1.2 points) decrease in the Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS28-ESR)Time frame: Week 12

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital"

    Chelyabinsk, Chelyabinsk Oblast, Russia

  • Limited Liability Company "Medical Center "Revma-Med"

    Kemerovo, Kemerovo Oblast, Russia

  • Limited Liability Company "OLLA-MED"

    Moscow, Moscow, Russia

  • Federal State Budgetary Institution "Research Institute of Rheumatology named after V.A. Nasonova"

    Moscow, Moscow, Russia

  • State budgetary healthcare institution of the city of Moscow "City Clinical Hospital No. 52 of the Moscow Health Department" (GBUZ "City Clinical Hospital No. 52 DZM")

    Moscow, Moscow, Russia

  • Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N. I. Pirogova

    Moscow, Moscow, Russia

  • Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N.I. Pirogov Ministry of Health of Russia Separate structural unit "Russian Gerontological Scientific and Clinical Center"

    Moscow, Moscow, Russia

  • Limited Liability Company "Medical Center "Healthy Family"

    Novosibirsk, Novosibirsk Oblast, Russia

  • Federal State Budgetary Educational Institution of Higher Education Orenburg State Medical University of the Ministry of Health of Russia

    Orenburg, Orenburg Oblast, Russia

  • Limited Liability Company "Medical Technologies" LLC "Medical Technologies"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Ex Seven Clinical Research"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Interleukin"

    Saint Petersburg, Sankt-Peterburg, Russia

  • State Budgetary Healthcare Institution Leningrad area Clinical Hospital

    Saint Petersburg, Sankt-Peterburg, Russia

  • Private foundation "RZD-Medicine" Smolensk"

    Smolensk, Smolensk Oblast, Russia

  • Limited Liability Company "BioMed"

    Vladimir, Vladimirskaya Oblast’, Russia

  • State health care institution city clinical hospital №25

    Volgograd, Volgograd Oblast, Russia

  • State Budgetary Healthcare Institution "Clinical Hospital No. 2"

    Yaroslavl, Yaroslavl Oblast, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.